Search

Your search keyword '"van Biezen, Anja"' showing total 436 results
Start Over Author "van Biezen, Anja"
436 results on '"van Biezen, Anja"'

51. Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation

Author

Schmid, Christoph, primary, de Wreede, Liesbeth C., additional, van Biezen, Anja, additional, Finke, Jürgen, additional, Ehninger, Gerhard, additional, Ganser, Arnold, additional, Volin, Liisa, additional, Niederwieser, Dietger, additional, Beelen, Dietrich, additional, Alessandrino, Paolo, additional, Kanz, Lothar, additional, Schleuning, Michael, additional, Passweg, Jakob, additional, Veelken, Hendrik, additional, Maertens, Johan, additional, Cornelissen, Jan J., additional, Blaise, Didier, additional, Gramatzki, Martin, additional, Milpied, Noel, additional, Yakoub-Agha, Ibrahim, additional, Mufti, Ghulam, additional, Rovira, Montserrat, additional, Arnold, Renate, additional, de Witte, Theo, additional, Robin, Marie, additional, and Kröger, Nikolaus, additional

Published
2017
Full Text
View/download PDF

52. Allogeneic hematopoietic cell transplantation for patients with TP53mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study

Author

Schetelig, Johannes, Hoek, Jennifer, Stilgenbauer, Stephan, Middeke, Jan Moritz, Andersen, Niels Smedegaard, Fox, Christopher P., Lenhoff, Stig, Volin, Liisa, Shimoni, Avichai, Schroyens, Wilfried, van Gelder, Michel, Bunjes, Donald, van Biezen, Anja, Baldauf, Henning, de Wreede, Liesbeth C., Tournilhac, Olivier, Kröger, Nicolaus, Yakoub-Agha, Ibrahim, and Dreger, Peter

Published
2021
Full Text
View/download PDF

53. Salvage use of allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the European Group for Blood and Marrow Transplant Chronic Malignancies Working Party

Author

Sobh, Mohamad, primary, Michallet, Mauricette, additional, Dubois, Valérie, additional, Iacobelli, Simona, additional, Koster, Linda, additional, Van Biezen, Anja, additional, Fegueux, Nathalie, additional, Tabrizi, Reza, additional, Finke, Jürgen, additional, El-Cheikh, Jean, additional, Schipperus, Martin, additional, Meijer, Ellen, additional, von dem Borne, Peter, additional, Petersen, Eefke, additional, Russell, Nigel, additional, Tholouli, Eleni, additional, Passweg, Jakob, additional, Garban, Frédéric, additional, Maertens, Johan, additional, Chevalier, Patrice, additional, Maillard, Natacha, additional, Volin, Liisa, additional, Francois, Sylvie, additional, Lioure, Bruno, additional, Beguin, Yves, additional, Gluckman, Eliane, additional, Ruggeri, Annalisa, additional, Garderet, Laurent, additional, and Kröger, Nicolaus, additional

Published
2017
Full Text
View/download PDF

54. Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

Author

Onida, Francesco, primary, de Wreede, Liesbeth C., additional, van Biezen, Anja, additional, Eikema, Diderik‐Jan, additional, Byrne, Jenny L., additional, Iori, Anna P., additional, Schots, Rik, additional, Jungova, Alexandra, additional, Schetelig, Johannes, additional, Finke, Jürgen, additional, Veelken, Hendrik, additional, Johansson, Jan‐Erik, additional, Craddock, Charles, additional, Stelljes, Matthias, additional, Theobald, Matthias, additional, Holler, Ernst, additional, Schanz, Urs, additional, Schaap, Nicolaas, additional, Bittenbring, Jörg, additional, Olavarria, Eduardo, additional, Chalandon, Yves, additional, and Kröger, Nicolaus, additional

Published
2017
Full Text
View/download PDF

55. Outcome of Third Salvage Autologous Stem Cell Transplantation in Multiple Myeloma

Author

Garderet, Laurent, primary, Iacobelli, Simona, additional, van Biezen, Anja, additional, Koster, Linda, additional, Dreger, Peter, additional, Johansson, Jan Erik, additional, Leleu, Xavier, additional, Potter, Michael, additional, Mayer, Jiri, additional, Peschel, Christian, additional, Zak, Pavel, additional, Ganser, Arnold, additional, Metzner, Bernd, additional, Saglio, Giuseppe, additional, Schafer-Eckart, Kerstin, additional, Pohlreich, David, additional, Tilly, Herve, additional, Grasso, Mariella, additional, Caillot, Denis, additional, Einsele, Herman, additional, Sengeloev, Henrik, additional, Bron, Dominique, additional, Ciceri, Fabio, additional, Schoenland, Stefan, additional, and kroger, Nicolaus, additional

Published
2017
Full Text
View/download PDF

56. Autologous Hematopoietic Cell Transplantation in Elderly Patients Aged 65 and Older: A Retrospective Analysis By the Complications and Quality of Life Working Party of the EBMT

Author

Sánchez-Ortega, Isabel, primary, Basak, Grzegorz W., additional, Beohou, Eric, additional, van der Werf, Steffie, additional, Labopin, Myriam, additional, van Biezen, Anja, additional, Kroeger, Nicolaus, additional, Montoto, Silvia, additional, Nagler, Arnon, additional, Dreger, Peter, additional, Goldschmidt, Hartmut, additional, Blaise, Didier, additional, Einsele, Hermann, additional, Finke, Jürgen, additional, Russell, Nigel H, additional, Haenel, Mathias, additional, Potter, Michael, additional, Caillot, Denis, additional, Salwender, Hans-Juergen, additional, Ljungman, Per T., additional, Craddock, Charles, additional, Garderet, Laurent, additional, Sureda, Anna, additional, Mohty, Mohamad, additional, Ruutu, Tapani, additional, and Duarte, Rafael F., additional

Published
2016
Full Text
View/download PDF

58. Outcome of Third Salvage Autologous Stem Cell Transplantation in Multiple Myeloma

Author

Garderet, Laurent, primary, Iacobelli, Simona, additional, van Biezen, Anja, additional, Koster, Linda, additional, Dreger, Peter, additional, Johansson, Jan-Erik, additional, Leleu, Xavier, additional, Potter, Michael, additional, Krejci, Marta, additional, Peschel, Christian, additional, Radocha, Jakub, additional, Ganser, Arnold, additional, Metzner, Bernd, additional, Paoli, Nicoli, additional, Schäfer-Eckart, Kerstin, additional, Pohlreich, David, additional, Lenain, Pascal, additional, Grasso, Mariella, additional, Caillot, Denis, additional, Einsele, Hermann, additional, Sengeloev, Henrik, additional, Meuleman, Nathalie, additional, Ciceri, Fabio, additional, Schönland, Stefan, additional, and Kröger, Nicolaus, additional

Published
2016
Full Text
View/download PDF

59. Comparison of Haematopoietic Stem Cell Transplantation Approaches in Primary Plasma Cell Leukaemia

Author

Lawless, Sarah, primary, Simona, Iacobelli, additional, van Biezen, Anja, additional, Koster, Linda, additional, Chevallier, Patrice, additional, Blaise, Didier, additional, Foà, Roberto, additional, Tabrizi, Reza, additional, Schaap, Nicolaas PM, additional, Lenhoff, Stig, additional, Russell, Nigel H., additional, Poiré, Xavier, additional, Petersen, Eefke, additional, Cornelissen, Jan J., additional, Di Bartolomeo, Paolo, additional, Wilson, Keith, additional, Schipperus, Martin, additional, Lioure, Bruno, additional, Arcese, William, additional, Mufti, Ghulam J, additional, Snowden, John A, additional, Finke, Jurgen, additional, Morris, Curly, additional, Garderet, Laurent, additional, Kröger, Nicolaus, additional, and Schönland, Stefan, additional

Published
2016
Full Text
View/download PDF

60. Relapse Risk Score after Allogeneic Stem Cell Transplantation for MDS Patients. an EBMT Study from the MDS Subcommittee of Chronic Malignancies Working Party (CMWP)

Author

Kröger, Nicolaus, primary, Putter, Hein, additional, De Wreede, Liesbeth, additional, van Biezen, Anja, additional, Ziagkos, Dimitris, additional, Volin, Liisa, additional, Maertens, Johan, additional, Finke, Jürgen, additional, Ljungman, Per T., additional, Russell, Nigel H., additional, Yakoub-Agha, Ibrahim, additional, Schaap, Michel, additional, Craddock, Charles, additional, Mufti, Ghulam J, additional, Chevallier, Patrice, additional, Passweg, Jakob R, additional, Milpied, Noel, additional, Blaise, Didier, additional, Bourhis, Jean-Henri, additional, Gedde-Dahl, Tobias, additional, Espiga, Carlos Richard, additional, Cornelissen, Jan J., additional, Göhring, Gudrun, additional, Schetelig, Johannes, additional, de Witte, Theo, additional, and Robin, Marie, additional

Published
2016
Full Text
View/download PDF

61. Identification of Baseline Characteristics That Predict Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Chronic Lymphocytic Leukemia Patients - a Retrospective Analysis from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.

Author

van Gelder, Michel, primary, Ziagkos, Dimitris, additional, de Wreede, Liesbeth C, additional, van Biezen, Anja, additional, Dreger, Peter, additional, Gramatzki, Martin, additional, Stelljes, Matthias, additional, Smedegaard Andersen, Niels, additional, Schaap, Nicolaas PM, additional, Vitek, Antonin, additional, Beelen, Dietrich, additional, Volin, Liisa, additional, Finke, Jürgen, additional, Passweg, Jakob R, additional, Ganser, Arnold, additional, Machaczka, Maciej J, additional, Delgado, Julio, additional, Krüger, William, additional, Faber, Edgar, additional, Socie, Gerard, additional, Jindra, Pavel, additional, Afanasyev, Boris V, additional, Theobald, Matthias, additional, Chalandon, Yves, additional, Henseler, Anja, additional, Schoenland, Stefan O., additional, Nicolaus, Kroger, additional, and Schetelig, Johannes, additional

Published
2016
Full Text
View/download PDF

62. Center Characteristics and Procedure-Related Factors Have an Impact on Outcomes of Allogeneic Transplantation for Patients with CLL: A Retrospective Analysis from the European Society for Blood and Marrow Transplantation (EBMT)

Author

Schetelig, Johannes, primary, de Wreede, Liesbeth C, additional, Andersen, Niels S., additional, Moreno, Carol, additional, van Gelder, Michel, additional, Vitek, Antonin, additional, Karas, Michal, additional, Michallet, Mauricette, additional, Machaczka, Maciej J, additional, Gramatzki, Martin, additional, Beelen, Dietrich W., additional, Finke, Jurgen, additional, Delgado, Julio, additional, Volin, Liisa, additional, Passweg, Jakob, additional, Dreger, Peter, additional, Schaap, Nicolaas PM, additional, Theobald, Matthias, additional, Henseler, Anja, additional, van Biezen, Anja, additional, Bornhaeuser, Martin, additional, Iacobella, Simona, additional, Putter, Hein, additional, Schönland, Stefen, additional, and Kröger, Nicolaus, additional

Published
2016
Full Text
View/download PDF

63. Outcome of Patients with Second Cancer after Hematopoietic Stem Cell Transplantation: On Behalf of the Complications and Quality of Life Working Party of the EBMT

Author

Tichelli, André, primary, Beohou, Eric, additional, Labopin, Myriam, additional, Socié, Gérard, additional, Rovó, Alicia, additional, Badoglio, Manuela, additional, van Biezen, Anja, additional, Basak, Grzegorz, additional, Duarte, Rafael F., additional, and Salooja, Nina, additional

Published
2016
Full Text
View/download PDF

64. Mother Donors Improve Outcomes after HLA Haploidentical Hematopoietic Transplantation: A Retrospective Study By the Cell Therapy and Immunobiology Working Party of the EBMT

Author

Velardi, Andrea, primary, Ruggeri, Loredana, additional, Ziagkos, Dimitris, additional, van Biezen, Anja, additional, Merluzzi, Mara, additional, Bondanza, Attilio, additional, Bootsman, Nathasja, additional, Massei, Maria Speranza, additional, Amico, Lucia, additional, Piccinelli, Sara, additional, Noviello, Maddalena, additional, Ciceri, Fabio, additional, Klingebiel, Thomas, additional, Koc, Yener, additional, Veelken, Hendrik, additional, Locatelli, Franco, additional, Arcese, William, additional, Gruhn, Bernd, additional, Salvi, Flavia, additional, Bonini, Chiara, additional, and van Rood, Jon J., additional

Published
2016
Full Text
View/download PDF

65. Comparison of Allogeneic Stem Cell Transplantation for Transformed Acute Myeloid Leukemia Derived from MDS, CMML or MPN. a Report of the Chronic Malignancies Working Party of EBMT

Author

Kröger, Nicolaus, primary, Eikema, Diderik-Jan, additional, De Wreede, Liesbeth, additional, van Biezen, Anja, additional, Beelen, Dietrich W., additional, Finke, Jürgen, additional, Koenecke, Christian, additional, Niederwieser, Dietger, additional, Bornhäuser, Martin, additional, Schönland, Stefan, additional, Mufti, Ghulam J, additional, Stuhler, Gernot, additional, Maertens, Johan, additional, Theobald, Matthias, additional, Kobbe, Guido, additional, Volin, Liisa, additional, Wulf, Gerald, additional, Kahls, Peter, additional, Milpied, Noel, additional, Greinix, Hildegard, additional, Masszi, Tamás, additional, Nagler, Arnon, additional, Chalandon, Yves, additional, and Robin, Marie, additional

Published
2016
Full Text
View/download PDF

66. Allogeneic Hematopoietic Cell Transplantation in Elderly Patients Aged 65 and Older: A Retrospective Analysis By the Complications and Quality of Life Working Party of the EBMT

Author

Basak, Grzegorz W., primary, Sánchez-Ortega, Isabel, additional, Beohou, Eric, additional, van der Werf, Steffie, additional, Labopin, Myriam, additional, van Biezen, Anja, additional, Dreger, Peter, additional, Montoto, Silvia, additional, DuFour, Carlo, additional, Kroger, Nicolaus, additional, Nagler, Arnon, additional, Ehninger, Gerhard, additional, Niederwieser, Dietger, additional, Finke, Jurgen, additional, Beelen, Dietrich W., additional, Kanz, Lothar, additional, Tischer, Johanna, additional, Stuhler, Gernot, additional, Mufti, Ghulam J, additional, Glass, Bertram, additional, Arnold, Renate, additional, Sureda, Anna, additional, Mohty, Mohamad, additional, Ruutu, Tapani, additional, and Duarte, Rafael F., additional

Published
2016
Full Text
View/download PDF

67. Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors

Author

Styczyński, Jan, Tridello, Gloria, Koster, Linda, Iacobelli, Simona, van Biezen, Anja, van der Werf, Steffie, Mikulska, Małgorzata, Gil, Lidia, Cordonnier, Catherine, Ljungman, Per, Averbuch, Diana, Cesaro, Simone, de la Camara, Rafael, Baldomero, Helen, Bader, Peter, Basak, Grzegorz, Bonini, Chiara, Duarte, Rafael, Dufour, Carlo, Kuball, Jurgen, Lankester, Arjan, Montoto, Silvia, Nagler, Arnon, Snowden, John A., Kröger, Nicolaus, Mohty, Mohamad, and Gratwohl, Alois

Abstract

Information on incidence, and factors associated with mortality is a prerequisite to improve outcome after hematopoietic stem cell transplantation (HSCT). Therefore, 55′668 deaths in 114′491 patients with HSCT (83.7% allogeneic) for leukemia were investigated in a landmark analysis for causes of death at day 30 (very early), day 100 (early), at 1 year (intermediate) and at 5 years (late). Mortality from all causes decreased from cohort 1 (1980–2001) to cohort 2 (2002–2015) in all post-transplant phases after autologous HSCT. After allogeneic HSCT, mortality from infections, GVHD, and toxicity decreased up to 1 year, increased at 5 years; deaths from relapse increased in all post-transplant phases. Infections of unknown origin were the main cause of infectious deaths. Lethal bacterial and fungal infections decreased from cohort 1 to cohort 2, not unknown or mixed infections. Infectious deaths were associated with patient-, disease-, donor type, stem cell source, center, and country- related factors. Their impact varied over the post-transplant phases. Transplant centres have successfully managed to reduce death after HSCT in the early and intermediate post-transplant phases, and have identified risk factors. Late post-transplant care could be improved by focus on groups at risk and better identification of infections of “unknown origin”.

Published
2020
Full Text
View/download PDF

69. Outcome of Allogeneic Stem Cell Transplantation for Patients Transformed to Myelodysplastic Syndrome or Leukemia from Severe Aplastic Anemia: A Report from the MDS Subcommittee of the Chronic Malignancies Working Party and the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation

Author

Hussein, Ayad Ahmed, Halkes, Constantijn M., Socié, Gérard, Tichelli, André, von dem Borne, Peter A., Schaap, Michel N.P.M., Foa, Robin, Ganser, Arnold, Dufour, Carlo, Bacigalupo, Andrea, Locasciulli, Anna, Aljurf, Mahmoud, Peters, Christina, Robin, Marie, van Biezen, Anja A., Volin, Liisa, De Witte, Theo, Marsh, Judith, Passweg, Jakob R., and Kröger, Nicolas

Published
2014
Full Text
View/download PDF

70. Allogeneic Stem Cell Transplantation for Myelofibrosis with Leukemic Transformation: A Study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation

Author

Alchalby, Haefaa, Zabelina, Tatjana, Stübig, Thomas, van Biezen, Anja, Bornhäuser, Martin, Di Bartolomeo, Paolo, Beelen, Dietrich, Cahn, Jean Yves, Dreger, Peter, Schroyens, William, de Witte, Theo, Olavarria, Eduardo, and Kröger, Nicolaus

Published
2014
Full Text
View/download PDF

71. Use of the quality management system 'JACIE' and outcome after hematopoietic stem cell transplantation

Author

Gratwohl, Alois, Brand, Roland, McGrath, Eoin, van Biezen, Anja, Sureda, Anna, Ljungman, Per, Baldomero, Helen, Chabannon, Christian, Apperley, Jane, Joint Accreditation Committee (JACIE), International Society for Cellular Therapy, European Group for Blood and Marrow Transplantatio, and European Leukemia Net

Subjects
Male, Quality Control, medicine.medical_specialty, Outcome assessment (Medical care), Quality Assurance, Health Care, medicine.medical_treatment, Improved survival, Hematopoietic stem cell transplantation, Stem cells, Accreditation, Recurrence, Risk Factors, Outcome Assessment, Health Care, medicine, Overall survival, Humans, Mortality, Intensive care medicine, Retrospective Studies, Patient Care Team, business.industry, Hazard ratio, Hematopoietic Stem Cell Transplantation, Hematology, Articles, Garantia de qualitat, Quality assurance, Transplantation, Quality management system, Cohort, Emergency medicine, Avaluació de resultats (Assistència mèdica), Female, business, Cèl·lules mare, Total Quality Management
Abstract

Competent authorities, healthcare payers and hospitals devote increasing resources to quality management systems but scientific analyses searching for an impact of these systems on clinical outcome remain scarce. Earlier data indicated a stepwise improvement in outcome after allogeneic hematopoietic stem cell transplantation with each phase of the accreditation process for the quality management system “JACIE”. We therefore tested the hypothesis that working towards and achieving “JACIE” accreditation would accelerate improvement in outcome over calendar time. Overall mortality of the entire cohort of 107,904 patients who had a transplant (41,623 allogeneic, 39%; 66,281 autologous, 61%) between 1999 and 2006 decreased over the 14-year observation period by a factor of 0.63 per 10 years (hazard ratio: 0.63; 0.58–0.69). Considering “JACIE“-accredited centers as those with programs having achieved accreditation by November 2012, at the latest, this improvement was significantly faster in “JACIE”-accredited centers than in non-accredited centers (approximately 5.3% per year for 49,459 patients versus approximately 3.5% per year for 58,445 patients, respectively; hazard ratio: 0.83; 0.71–0.97). As a result, relapse-free survival (hazard ratio 0.85; 0.75–0.95) and overall survival (hazard ratio 0.86; 0.76–0.98) were significantly higher at 72 months for those patients transplanted in the 162 “JACIE“-accredited centers. No significant effects were observed after autologous transplants (hazard ratio 1.06; 0.99–1.13). Hence, working towards implementation of a quality management system triggers a dynamic process associated with a steeper reduction in mortality over the years and a significantly improved survival after allogeneic stem cell transplantation. Our data support the use of a quality management system for complex medical procedures.

Published
2014

72. Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxide

Author

Morris, Curly, de Wreede, Liesbeth, Scholten, Marijke, Brand, Ronald, van Biezen, Anja, Sureda, Anna, Dickmeiss, Ebbe, Trneny, Marek, Apperley, Jane, Chiusolo, Patrizia, van Imhoff, Gustaaf W., Lenhoff, Stig, Martinelli, Giovanni, Hentrich, Marcus, Pabst, Thomas, Onida, Francesco, Quinn, Michael, Kroger, Nicolaus, de Witte, Theo, Ruutu, Tapani, Damage and Repair in Cancer Development and Cancer Treatment (DARE), and Stem Cell Aging Leukemia and Lymphoma (SALL)

Subjects
Settore MED/15 - MALATTIE DEL SANGUE, FLUID MANAGEMENT DEVICE, BONE-MARROW, MULTIPLE-MYELOMA, INFUSION, CLINICAL TOXICITY, STEM-CELL TRANSPLANTATION, LONG-TERM CRYOPRESERVATION, SEVERE RESPIRATORY DEPRESSION, ADVERSE EVENTS, HEMATOPOIETIC PROGENITOR CELLS, dmso
Abstract

BackgroundDimethyl sulfoxide (DMSO) is essential for the preservation of liquid nitrogen-frozen stem cells, but is associated with toxicity in the transplant recipient. Study Design and MethodsIn this prospective noninterventional study, we describe the use of DMSO in 64 European Blood and Marrow Transplant Group centers undertaking autologous transplantation on patients with myeloma and lymphoma and analyze side effects after return of DMSO-preserved stem cells. ResultsWhile the majority of centers continue to use 10% DMSO, a significant proportion either use lower concentrations, mostly 5 or 7.5%, or wash cells before infusion (some for selected patients only). In contrast, the median dose of DMSO given (20mL) was much less than the upper limit set by the same institutions (70mL). In an accompanying statistical analysis of side effects noted after return of DMSO-preserved stem cells, we show that patients in the highest quartile receiving DMSO (mL and mL/kg body weight) had significantly more side effects attributed to DMSO, although this effect was not observed if DMSO was calculated as mL/min. Dividing the myeloma and lymphoma patients each into two equal groups by age we were able to confirm this result in all but young myeloma patients in whom an inversion of the odds ratio was seen, possibly related to the higher dose of melphalan received by young myeloma patients. ConclusionWe suggest better standardization of preservation method with reduced DMSO concentration and attention to the dose of DMSO received by patients could help reduce the toxicity and morbidity of the transplant procedure.

Published
2014

73. Treatment options for relapse after autograft in multiple myeloma – report from an EBMT educational meeting

Author

Garderet, Laurent, primary, Cook, Gordon, additional, Auner, Holger W., additional, Bruno, Benedetto, additional, Lokhorst, Henk, additional, Perez-Simon, Jose Antonio, additional, Sahebi, Firoozeh, additional, Scheid, Christof, additional, Morris, Curly, additional, van Biezen, Anja, additional, Sobh, Mohamad, additional, Michallet, Mauricette, additional, Gahrton, Gösta, additional, Schönland, Stefan, additional, and Kröger, Nicolaus, additional

Published
2016
Full Text
View/download PDF

74. High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation

Author

Cook, Gordon, primary, Iacobelli, Simona, additional, van Biezen, Anja, additional, Ziagkos, Dimitris, additional, LeBlond, Veronique, additional, Abraham, Julie, additional, McQuaker, Grant, additional, Schoenland, Stefan, additional, Rambaldi, Alessandro, additional, Halaburda, Kazimierz, additional, Rovira, Maria, additional, Sica, Simona, additional, Byrne, Jenny, additional, Sanz, Ramon Garcia, additional, Nagler, Arnon, additional, van de Donk, Niels W.C.J., additional, Sinisalo, Marjatta, additional, Cook, Mark, additional, Kröger, Nicolaus, additional, De Witte, Theo, additional, Morris, Curly, additional, and Garderet, Laurant, additional

Published
2016
Full Text
View/download PDF

75. Allogeneic Stem Cell Transplantation for MDS Patients More Than 70 Years of Age: a Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party (CMWP) of the EBMT

Author

Heidenreich, Silke, primary, Ziagkos, Dimitris, additional, van Biezen, Anja, additional, Finke, Jürgen, additional, Platzbecker, Uwe, additional, Niederwieser, Dietger, additional, Einsele, Hermann, additional, Bethge, Wolfgang A, additional, Schleuning, Michael, additional, Beelen, Dietrich W., additional, Tischer, Johanna, additional, Nagler, Arnon, additional, Glass, Bertram, additional, Maertens, Johan, additional, Richard, Carlos, additional, Beguin, Yves, additional, Sill, Heinz, additional, de Witte, Theo, additional, Robin, Marie, additional, and Kroeger, Nicolaus, additional

Published
2015
Full Text
View/download PDF

76. Allogeneic Hematopoietic Transplantation in Patients with CLL: Results of a Large Disease-Specific Risk Factor Analysis

Author

Schetelig, Johannes, primary, de Wreede, Liesbeth, additional, van Gelder, Michel, additional, Smedegaard Andersen, Niels, additional, Moreno, Carol, additional, Vitek, Antonin, additional, Karas, Michal, additional, Michallet, Mauricette, additional, Machaczka, Maciej J, additional, Gramatzki, Martin, additional, Beelen, Dietrich, additional, Finke, Jürgen, additional, Urbano-Ispizúa, Álvaro, additional, Volin, Liisa, additional, Passweg, Jakob R., additional, Dreger, Peter, additional, Henseler, Anja, additional, van Biezen, Anja, additional, Bornhäuser, Martin, additional, Schoenland, Stefan, additional, and Kröger, Nicolaus, additional

Published
2015
Full Text
View/download PDF

77. Outcome of Patients with Myelofibrosis Relapsing after Allogeneic Stem Cell Transplant: A Retrospective Study By the Chronic Malignancies Working Party of EBMT

Author

McLornan, Donal, primary, Szydlo, Richard, additional, van Biezen, Anja, additional, Koster, Linda, additional, Klyuchnikov, Evgeny, additional, Bacigalupo, Andrea, additional, Schleuning, Michael, additional, Finke, Jurgen, additional, Vitek, Antonin, additional, Peniket, Andrew, additional, Beelen, Dietrich W., additional, Craddock, Charles, additional, Apperley, Jane F., additional, Bethge, Wolfgang, additional, Blaise, Didier, additional, Niederwieser, Dietger, additional, Volin, Liisa, additional, Dreger, Peter, additional, Michallet, Mauricette, additional, Nagler, Arnon, additional, Arnold, Renate, additional, Olavarria, Eduardo, additional, and Kroeger, Nicolaus, additional

Published
2015
Full Text
View/download PDF

78. The EBMT Score Predicts Transplant Related Mortality and Overall Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes

Author

Lozano, Sara, primary, Olavarria, Eduardo, additional, Iacobelli, Simona, additional, van Biezen, Anja, additional, Beelen, Dietrich W., additional, Finke, Jurgen, additional, Mufti, Ghulam J, additional, Niederwieser, Dietger, additional, Ehninger, Gerhard, additional, Ganser, Arnold, additional, Stuhler, Gernot, additional, Maertens, Johan, additional, Bacigalupo, Andrea, additional, Volin, Liisa, additional, Nagler, Arnon, additional, Kobbe, Guido, additional, Schönland, Stefan, additional, de Witte, Theo, additional, Kröger, Nicolaus, additional, and Robin, Marie, additional

Published
2015
Full Text
View/download PDF

81. Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndrome (MDS) Patients at Lower Risk According to International Prognostic Scoring System (IPSS) : A Retrospective Study on Behalf of the Cmwp of the EBMT

Author

Robin, Marie, primary, Raphael, Porcher, additional, van Biezen, Anja, additional, Volin, Liisa, additional, Mufti, Ghulam J., additional, Craddock, Charles, additional, Finke, Jurgen, additional, Richard Espiga, Carlos, additional, Passweg, Jakob, additional, Peniket, Andrew, additional, Maertens, Johan, additional, Sucak, Gulsan, additional, Gedde-Dahl, Tobias, additional, Vitek, Antonin, additional, Nagler, Arnon, additional, Blaise, Didier, additional, Beelen, Dietrich, additional, Maillard, Natacha, additional, Schwerdtfeger, Rainer, additional, Iacobelli, Simona, additional, de Witte, Theo, additional, and Kroeger, Nicolaus, additional

Published
2014
Full Text
View/download PDF

82. Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Evolution and Outcomes over More Than Two Decades within EBMT Centers

Author

Michallet, Mauricette, primary, Sobh, Mohamad, additional, Iacobelli, Simona, additional, van Biezen, Anja, additional, Dreger, Peter, additional, Petersen, Eefke, additional, Schaap, Nicolaas PM, additional, Bandini, Giuseppe, additional, Volin, Liisa, additional, Meijer, Ellen, additional, Niederwieser, Dietger, additional, Einsele, Hermann, additional, Blaise, Didier, additional, Tabrizi, Reza, additional, Vincent, Laure, additional, Finke, Jurgen, additional, Bunjes, Donald, additional, Cornelissen, Jan J., additional, Gahrton, Gosta, additional, Garderet, Laurent, additional, and Kroger, Nicolaus, additional

Published
2014
Full Text
View/download PDF

83. Long-Term Follow-up Data Support the Curative Potential of Allogeneic Hematopoietic Cell Transplantation in Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis from the Chronic Malignancies Working Party of the EBMT

Author

Van Gelder, Michel, primary, de Wreede, Liesbeth, additional, Henseler, Anja, additional, van Biezen, Anja, additional, Niederwieser, Dietger, additional, Karas, Michal, additional, Andersen, Niels S., additional, Gramatzki, Martin, additional, Dreger, Peter, additional, Bunjes, Donald W., additional, Petersen, Eefke J, additional, Potter, Michael N, additional, Beelen, Dietrich, additional, Yakoub-Agha, Ibrahim, additional, Cornelissen, Jan J, additional, Russell, Nigel, additional, Finke, Jurgen, additional, Schoemans, Helene, additional, Blaise, Didier, additional, Shankara, Paneesha, additional, Vitek, Antonin, additional, Bornhäuser, Martin, additional, Schönland, Stefan, additional, Kröger, Nicolaus, additional, and Schetelig, Johannes, additional

Published
2014
Full Text
View/download PDF

84. Similar Outcome of Upfront Unrelated and Matched Sibling Donor Hematopoietic Stem Cell Transplantation in Idiopathic Aplastic Anaemia of Childhood and Adolescence: A Cohort Controlled Study on Behalf of the UK Paediatric BMT WP, of the PD WP and of the SAA WP of the EBMT

Author

Dufour, Carlo, primary, Pillon, Marta, additional, Carraro, Elisa, additional, Bhatnagar, Neha, additional, Wynn, Rob, additional, Gibson, Brenda, additional, Vora, Ajay J, additional, Steward, Colin G, additional, Ewins, Anna Maria, additional, Hough, Rachael E, additional, de la Fuente, Josu, additional, Velangi, Mark, additional, Veys, Paul, additional, Amrolia, Persis J, additional, Skinner, Roderick, additional, Bacigalupo, Andrea, additional, Risitano, Antonio M., additional, Socie, Gerard, additional, Peffault de Latour, Regis, additional, Passweg, Jakob, additional, Rovo, Alicia, additional, Tichelli, André, additional, Schrezenmeier, Hubert, additional, Hochsmann, Britta, additional, Bader, Peter, additional, van Biezen, Anja, additional, Marsh, Judith C, additional, Aljurf, Mahmoud D., additional, and Samarasinghe, Sujiith, additional

Published
2014
Full Text
View/download PDF

85. Allogeneic HCT in Patients with 17p-CLL: Results of a Non-Interventional Study of the EBMT & Eric

Author

Schetelig, Johannes, primary, Hoek, Jennifer, additional, Stilgenbauer, Stephan, additional, Bornhäuser, Martin, additional, Andersen, Niels S., additional, Fox, Christopher P, additional, Lenhoff, Stig, additional, Bunjes, Donald W., additional, Volin, Liisa, additional, Shimoni, Avichai, additional, Schroyens, Wilfried A, additional, van Gelder, Michel, additional, van Biezen, Anja, additional, de Wreede, Liesbeth, additional, de Witte, Theo M, additional, Kröger, Nicolaus, additional, and Dreger, Peter, additional

Published
2014
Full Text
View/download PDF

86. Allogeneic Stem Cell Transplantation in Myelodysplastic Syndrome; A More Favorable Outcome after Fludarabine and Treosulfan Conditioning. a Survey on Behalf of the Chronic Malignancies Working Party of the EBMT

Author

Shimoni, Avichai, primary, Nagler, Arnon, additional, Iacobelli, Simona, additional, van Biezen, Anja, additional, Beelen, Dietrich, additional, Mufti, Ghulam J., additional, Ciceri, Fabio, additional, Kanz, Lothar, additional, Volin, Liisa, additional, Richard, Carlos, additional, Blaise, Didier, additional, Ganser, Arnold, additional, Luft, Thomas, additional, Chevallier, Patrice, additional, Schwerdtfeger, Rainer, additional, de Witte, Theo, additional, Robin, Marie, additional, and Kröger, Nicolaus, additional

Published
2014
Full Text
View/download PDF

87. Allogene stamceltransplantatie in Nederland

Author

Schattenberg, A. V. M. B., Schouten, Harry C., Verdonck, Leo F., Willemze, Roel, van der Lelie, J., Huijgens, Peter C., van Imhoff, Gustaaf W., van Biezen, Anja, Brand, Ronaldt, Hagenbeek, A., de Witte, Theo, Cornelissen, Jan J., Cancer Center Amsterdam, and Clinical Haematology

Published
2009

88. Comparison of Haematopoietic Stem Cell Transplantation Approaches in Primary Plasma Cell Leukaemia

Author

Lawless, Sarah, Iacobelli, Simona, van Biezen, Anja, Koster, Linda, Chevallier, Patrice, Blaise, Didier, Foa, Roberto, Tabrizi, Reza, Schaap, N., Lenhoff, Stig, Russell, Nigel, Petersen, Eefke, Cornelissen, J.J., Di Bartolomeo, Paolo, Wilson, Keith, Dreger, Peter, Schipperus, M.R., Lioure, Bruno, Arcese, William, Mufti, G.J., Snowden, John, Finke, Jurgen, Morris, Curly, Garderet, Laurent, and Nicolaus Kroger

Published
2017
Full Text
View/download PDF

89. Treatment options for relapse after autograft in multiple myeloma – report from an EBMT educational meeting.

Author

Garderet, Laurent, Cook, Gordon, Auner, Holger W., Bruno, Benedetto, Lokhorst, Henk, Perez-Simon, Jose Antonio, Sahebi, Firoozeh, Scheid, Christof, Morris, Curly, van Biezen, Anja, Sobh, Mohamad, Michallet, Mauricette, Gahrton, Gösta, Schönland, Stefan, and Kröger, Nicolaus

Subjects
DISEASE relapse, AUTOGRAFTS, MULTIPLE myeloma treatment, STEM cell transplantation, HEALTH of patients, PHYSIOLOGY, THERAPEUTICS
Abstract

Major improvements have been made in the treatment of myeloma. However, all patients, perhaps with some exceptions, eventually relapse, even after autologous stem cell transplantation (ASCT). In that setting, the combinations of new drugs, namely the IMiDs and the proteasome inhibitors along with steroids, give encouraging results in relapsed patients. The median progression-free survival (PFS) is 20 months with lenalidomide plus dexamethasone plus ixazomib and 26 months with lenalidomide plus dexamethasone plus carfilzomib. Monoclonal antibodies have emerged as an additional new treatment option. The antibody anti-SLAMF7, elotuzumab, in combination with lenalidomide plus dexamethasone gives a median PFS of 20 months. The antibody daratumumab, targeting CD38, alone has an outstanding activity in previously heavily treated patients. Its use in combination is ongoing. Transplantation remains a major treatment option. For patients who relapse at least 18 months from the initial ASCT, a second ASCT can be performed with an expected time to progression of 19 months from the time of transplantation. For patients relapsing earlier and/or with high-risk characteristics and who are still chemosensitive, with a suitable donor, an allogeneic transplantation can be considered. The optimal treatment combination and sequence remain to be determined. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

90. Comparison Of Unrelated Cord Blood (CB) and Peripheral Blood Stem Cell (PB) Transplantation In Adults With Myelodysplastic Syndrome (MDS) After Reduced Intensity Conditioning Regimen (RIC): A Collaborative Study From Eurocord and Chronic Malignancies Working Party (CMWP-EBMT)

Author

Robin, Marie, primary, Ruggeri, Annalisa, additional, Labopin, Myriam, additional, Niederwieser, Dietger, additional, Tabrizzi, Reza, additional, Sanz, Guillermo, additional, Bourhis, Jean-Henri, additional, van Biezen, Anja, additional, Koenecke, Christian, additional, Blaise, Didier, additional, Tischer, Johanna, additional, Craddock, Charles, additional, Maillard, Natacha, additional, Mohty, Mohamad, additional, Russel, Nigel, additional, Schetelig, Johannes, additional, Finke, Jürgen, additional, Gluckman, Eliane, additional, de Witte, Theo M., additional, Rocha, Vanderson, additional, and Kroeger, Nicolaus, additional

Published
2013
Full Text
View/download PDF

91. Reduced Intensity Allogeneic Stem Cell Transplant In Patients With Multiple Myeloma: A Comparison Of Planned Autologous-Reduced Intensity Allogeneic Stem Cell Transplant (Auto-Allo) and Reduced Intensity Allogeneic Stem Cell Transplant (RIC) As Upfront Transplant In Patients With Multiple Myeloma, An EBMT Analysis

Author

Sahebi, Firoozeh, primary, Iacobelli, Simona, additional, Van Biezen, Anja, additional, Volin, Liisa, additional, Dreger, Peter, additional, Michallet, Mauricette, additional, Ljungman, Per T., additional, Gahrton, Goesta, additional, Morris, Curly TCM, additional, Schonland, Stefan, additional, de Witte, Theo, additional, Garderet, Laurent, additional, Kroeger, Nicolaus, additional, Henseler, Anja, additional, Schaap, Nicolaas PM, additional, Caballero, D, additional, Poire, Xavier, additional, Passweg, Jakob, additional, and Hamljadi, Rose-Marie, additional

Published
2013
Full Text
View/download PDF

92. Outcomes Of Haematopoietic Stem Cell Transplantation (HSCT) for Severe Congenital Neutropenia (SCN): Preliminary Results

Author

Fioredda, Francesca, primary, de Wreede, Liesbeth C, additional, Calvillo, Michaela, additional, Gaspar, Bobby, additional, Aljurf, Mahmoud, additional, van Biezen, Anja, additional, Morreale, Giuseppe, additional, Peters, Christina, additional, Knoedler, Erica M, additional, Al-Seraihy, Amal, additional, Yesilipek, M. Akif, additional, Fisher, Alain, additional, Bierings, Marc, additional, Donadieu, Jean, additional, Ozturk, Gulyuz, additional, Bourge, Francoise, additional, Bordon, Victoria, additional, Smith, Owen, additional, Bacigalupo, Andrea, additional, Passweg, Jakob, additional, Socie, Gerard, additional, Shretzenmeier, Hubert, additional, Marsh, Judith, additional, and Dufour, Carlo, additional

Published
2013
Full Text
View/download PDF

93. The Role Of High Dose Chemotherapy and Autologous Stem Cell Transplantation (ASCT) In Patients With POEMS Syndrome: A Retrospective study Of The Plasma Cell Disorders Subcommittee Of The Chronic Malignancy Working Party Of The EBMT

Author

Cook, Gordon, primary, Garderet, Laurent, additional, Iacobelli, Simona, additional, Morris, Curly, additional, Kroeger, Nikolaus, additional, van Biezen, Anja, additional, Rovira, M, additional, Byrne, Jenny, additional, Bordessoule, Dominique, additional, Leone, Giuseppe, additional, Nagler, Arnon, additional, Cook, Mark, additional, Legros, Laurence, additional, Ossenkoppele, Gert J., additional, Sanz, R Gacria, additional, Hoek, Jennifer, additional, and Castagna, Luca, additional

Published
2013
Full Text
View/download PDF

94. Allogeneic Hematopoietic Stem Cell Transplantation Is Feasible After Solid Organ Transplantation: A Retrospective Analysis By The Early Complications Subcommittee Of The Complications and Quality Of Life Working Party, EBMT

Author

Basak, Grzegorz W., primary, Jedrzejczak, Wieslaw W., additional, Schoemans, Helene, additional, Ljungman, Per T., additional, Kobbe, Guido, additional, Beguin, Yves, additional, Lang, Peter, additional, Sykora, Karl-Walter, additional, CJ te Boome, Liane, additional, van Biezen, Anja, additional, van der Werf, Steffie, additional, Mohty, Mohamad, additional, de Witte, Theo, additional, Marsh, Judith, additional, Dreger, Peter, additional, Kroeger, Nicolaus, additional, Duarte, Rafael F., additional, and Ruutu, Tapani, additional

Published
2013
Full Text
View/download PDF

95. Comparison Of Intensive Chemotherapy and Hypomethylating Agents Prior To Allogeneic Stem Cell Transplantation For Advanced MDS (RAEB, RAEB-T). A Study Of The MDS Subcommittee Of The Cmwp Of EBMT

Author

Potter, Victoria T, primary, Iacobelli, Simona, additional, van Biezen, Anja, additional, Maertens, Johann, additional, Bourhis, Jean-Henri, additional, Passweg, Jakob R., additional, Yakhoub-Agha, I, additional, Tabrizi, Reza, additional, Bay, Jacques-Olivier, additional, Robin, Marie, additional, Chevallier, Patrice, additional, Chalandon, Yves, additional, Huynh, Anne, additional, de Witte, Theo, additional, and Kroeger, Nikolaus, additional

Published
2013
Full Text
View/download PDF

96. Prognostic Value Of Five-Group Cytogenetic Risk Classification In Patients With MDS After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Multicenter Study Of The Chronic Malignancies Working Party Of The EBMT

Author

Koenecke, Christian, primary, Göhring, Gudrun, additional, de Wreede, Liesbeth, additional, van Biezen, Anja, additional, Scheid, Christof, additional, Volin, Liisa, additional, Maertens, Johan, additional, Finke, Juergen, additional, Schaap, Nicolaas PM, additional, Robin, Marie, additional, Passweg, Jakob R., additional, Cornelissen, Jan J, additional, Beelen, Dietrich, additional, Heuser, Michael, additional, de Witte, Theo, additional, and Kröger, Nicolaus, additional

Published
2013
Full Text
View/download PDF

97. The Revised IPSS (IPSS-R) At Transplant Predicts Overall and Relapse-Free Survival After Allogeneic Stem Cell Transplantation In MDS/sAML: A Retrospective Analysis Of The EBMT Chronic Malignancies Working Party

Author

Scheid, Christof, primary, de Wreede, Liesbeth, additional, van Biezen, Anja, additional, Göhring, Gudrun, additional, Koenecke, Christian, additional, Violin, Liisa, additional, Maertens, Johan, additional, Finke, Jürgen, additional, Schaap, Nicolaas PM, additional, Passweg, Jakob, additional, Socie, Gerard, additional, Beelen, Dietrich, additional, Cornelissen, Jan, additional, de Witte, Theo M., additional, and Kroeger, Nikolaus, additional

Published
2013
Full Text
View/download PDF

98. Comparison of Allogeneic Stem Cell Transplantation and Non-Transplant Approaches in Elderly Patients with Advanced Myelodysplastic Syndrome: Optimal Statistical Approaches and a Critical Appraisal of Clinical Results Using Non-Randomized Data

Author

Brand, Ronald, primary, Putter, Hein, additional, van Biezen, Anja, additional, Niederwieser, Dietger, additional, Martino, Rodrigo, additional, Mufti, Ghulam, additional, Onida, Francesco, additional, Symeonidis, Argiris, additional, Schmid, Christoph, additional, Garderet, Laurent, additional, Robin, Marie, additional, van Gelder, Michel, additional, Finke, Jürgen, additional, Bornhäuser, Martin, additional, Kobbe, Guido, additional, Germing, Ulrich, additional, de Witte, Theo, additional, and Kröger, Nicolaus, additional

Published
2013
Full Text
View/download PDF

99. Use Of a Quality Management System and Outcome After Hematopoietic Stem Cell Transplantation

Author

Jane F. Apperley, Ronald Brand, Christian Chabannon, Anna Sureda, van Biezen Anja, Helen Baldomero, Per Ljungman, Alois Gratwohl, and Eoin McGrath

Subjects
medicine.medical_specialty, Allogeneic transplantation, business.industry, Incidence (epidemiology), medicine.medical_treatment, Immunology, Retrospective cohort study, Cell Biology, Hematology, Hematopoietic stem cell transplantation, Biochemistry, Transplantation, Emergency medicine, Cohort, Health care, medicine, business, Accreditation
Abstract

Background Competent authorities, healthcare payers and hospitals devote increasing resources for quality management systems (QMS) and accreditation/certification of parts or all of their activities. Scientific analyses searching for an impact on clinical outcome remain scarce. Hematopoietic Stem Cell Transplantation (HSCT) involves complex processes and requires the collaboration of multiple categories of health care professionals. Despite major improvements over time, it remains associated with significant mortality and might serve as a role model for any QMS. The Joint Accreditation Committee of the International Society of Cellular Therapy Europe (ISCT) and the European Group for Blood and Marrow Transplantation (EBMT) – JACIE – has developed in collaboration with its US counterpart FACT standards that require a QMS. These principles apply to clinical management, cell collection and cell processing. Centers seeking accreditation are subject to a detailed document review, on-site inspection and auditing procedures. Earlier data indicated a stepwise improvement with each phase of the accreditation process (JCO 2011). Objective To test the hypothesis that working towards and achieving accreditation for the QMS “JACIE” would accelerate improvement in outcome over calendar time and, to quantify the potential impact on outcome. Design, setting and Patients A retrospective observational study of the previously published and well defined cohort of 107,904 patients treated with HSCT (41,623 allogeneic, 39%; 66,281 autologous, 61%) between 1999 and 2006, reported to the EBMT database and with substantially increased, complete follow-up information up to November 2012. A “JACIE+ “ center was defined as one which initiated the accreditation process and achieved accreditation at some point during the 14 year period, the latest by November 2012. Focus of the statistical approach was on the interaction between “JACIE+“ and calendar time on mortality reduction with adjustments for the key known risk factors. A completely different analysis framework has been chosen to test the hypothesis and to verify consistency between the two approaches. Main outcomes and measures: The primary outcome measure was reduction in overall mortality at 72 months over calendar time for 49,459 patients having received their transplant in a “JACIE+ “ center; 58,445 patients whose center never obtained accreditation served as baseline (“JACIE-”). Results Overall mortality of the entire cohort decreased over the 14 years observation period by a factor of 0.67 per 10 years (HR: 0.67; 0.62-0.73). This improvement was significantly faster in “JACIE+ “ (approx. 5% per year; HR per 10 years: HR: 0.62) than in “JACIE- “ (approx. 3% per year; HR per 10 years: HR: 0.73) centers. This difference in speed of mortality reduction was quantified by a HR of 0.85 (0.73-0.99) and resulted in a marked difference in outcome between the “JACIE+” and “JACIE-” centers: adjusted non relapse mortality (HR 0.93; 0.83-1.04) and relapse incidence (HR 0.94; 0.88-0.99) were lower, while relapse free (HR 0.94; 0.88-0.99) and overall survival (HR 0.91; 0.85-0.97) were significantly higher at 72 months after allogeneic transplantation for those patients transplanted in the 162 “JACIE+ “ centers. No effects of “JACIE” accreditation were observed after autologous HSCT, not on speed of mortality reduction nor on overall survival (HR 1.06; 0.99-1.13). Conclusions and relevance Working towards and implementation of a QMS triggers a dynamic process which is associated with a steeper reduction in mortality over the years and a significantly improved survival after allogeneic HSCT. Our data support the use of a QMS for allogeneic HSCT as well as for other forms of complex medical procedures. Disclosures: No relevant conflicts of interest to declare.

Published
2013

100. Response to Rituximab-Based Therapy and Risk Factor Analysis in Epstein Barr Virus–Related Lymphoproliferative Disorder After Hematopoietic Stem Cell Transplant in Children and Adults: A Study From the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation

Author

Styczynski, Jan, primary, Gil, Lidia, additional, Tridello, Gloria, additional, Ljungman, Per, additional, Donnelly, J. Peter, additional, van der Velden, Walter, additional, Omar, Hamdy, additional, Martino, Rodrigo, additional, Halkes, Constantijn, additional, Faraci, Maura, additional, Theunissen, Koen, additional, Kalwak, Krzysztof, additional, Hubacek, Petr, additional, Sica, Simona, additional, Nozzoli, Chiara, additional, Fagioli, Franca, additional, Matthes, Susanne, additional, Diaz, Miguel A., additional, Migliavacca, Maddalena, additional, Balduzzi, Adriana, additional, Tomaszewska, Agnieszka, additional, Camara, Rafael de la, additional, van Biezen, Anja, additional, Hoek, Jennifer, additional, Iacobelli, Simona, additional, Einsele, Hermann, additional, and Cesaro, Simone, additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results